ATP Citrate (pro-S)-Lyase
"ATP Citrate (pro-S)-Lyase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme that, in the presence of ATP and COENZYME A, catalyzes the cleavage of citrate to yield acetyl CoA, oxaloacetate, ADP, and ORTHOPHOSPHATE. This reaction represents an important step in fatty acid biosynthesis. This enzyme was formerly listed as EC 4.1.3.8.
| Descriptor ID |
D001275
|
| MeSH Number(s) |
D08.811.913.050.331
|
| Concept/Terms |
ATP Citrate (pro-S)-Lyase- ATP Citrate (pro-S)-Lyase
- Citrate Cleavage Enzyme
- Cleavage Enzyme, Citrate
- ATP Citrate Synthase
- Citrate Synthase, ATP
- Synthase, ATP Citrate
- ATP-Dependent Citrate Lyase
- ATP Dependent Citrate Lyase
- Citrate Lyase, ATP-Dependent
- Lyase, ATP-Dependent Citrate
- ATP Citrate (pro-3S)-Lyase
- ATP Citrate Lyase
- Citrate Lyase, ATP
- Lyase, ATP Citrate
|
Below are MeSH descriptors whose meaning is more general than "ATP Citrate (pro-S)-Lyase".
Below are MeSH descriptors whose meaning is more specific than "ATP Citrate (pro-S)-Lyase".
This graph shows the total number of publications written about "ATP Citrate (pro-S)-Lyase" by people in this website by year, and whether "ATP Citrate (pro-S)-Lyase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "ATP Citrate (pro-S)-Lyase" by people in Profiles.
-
ATP-citrate lyase is essential for high glucose-induced histone hyperacetylation and fibrogenic gene upregulation in mesangial cells. Am J Physiol Renal Physiol. 2017 Aug 01; 313(2):F423-F429.
-
ETC-1002: a future option for lipid disorders? Atherosclerosis. 2014 Dec; 237(2):705-10.
-
Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013 Sep 24; 62(13):1154-62.